Heat Biologics (HTBX)

NightHawk Biosciences, Inc. is an integrated biopharmaceutical company that engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform includes ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells, and ComPACT, which delivers antigen-driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer, and HS-130, which is in a Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in a Phase I clinical trial, and DR3/TNFRSF25 for various immunotherapy approaches. Additionally, the company is developing a COVID-19 vaccine, which is in the preclinical stage. NightHawk Biosciences has a collaboration with Dr. James Shapiro at the University of Alberta to manufacture a surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina.